• EuroEspes is a company located in Bergondo (Corunna, Spain), devoted to medical services and research.
  • As tradition requires, its president, Ramón Cacabelos García, rang the bell at the Stock Exchange.
  • EuroEspes thus becomes the third Spanish company in the biotechnology sector to join this select market.

The price of EuroEspes’ shares has been set at 2.80 euros, the same reference value approved by the EuroEspes General Meeting held on November 29th 2010. Furthermore, at this General Meeting it was agreed to execute a stock split of each old share into one hundred new shares by means of the reduction of their nominal value. Subsequent to this split, EuroEspes’ share capital amounts to 3,337,360.11 euros represented by 5,552,900 shares valued at 0.601012 euros each.
The company’s stock exchange listing bears the trading code EEP. Trading will be carried out by means of a pricing system according to the confluence of buy and sell orders by means of two daily auction periods or “fixings” (12:00h and 16:00h).
During the process of EuroEspes’ joining the MAB, Ernst & Young will act as Registered Advisor and the Banco de Sabadell as Liquidity Provider.
The third biotechnology company at the MAB
The EuroEspes Biomedical Research Center has today become the third Spanish company and the first Galician company of the biotechnology sector to be listed at the MAB.
EuroEspes, with its headquarters in Bergondo (Corunna, Spain) is a leading company in genomic medicine and nervous system disorders, with cutting-edge patents in nutraceutical bioproducts and pharmacogenomics.

2,80 euros por acción

The price of EuroEspes’ shares has been set at 2.80 euros, the same reference value approved by the EuroEspes General Meeting held on November 29th 2010. Furthermore, at this General Meeting it was agreed to execute a stock split of each old share into one hundred new shares by means of the reduction of their nominal value. Subsequent to this split, EuroEspes’ share capital amounts to 3,337,360.11 euros represented by 5,552,900 shares valued at 0.601012 euros each.
The company’s stock exchange listing bears the trading code EEP. Trading will be carried out by means of a pricing system according to the confluence of buy and sell orders by means of two daily auction periods or “fixings” (12:00h and 16:00h).
During the process of EuroEspes’ joining the MAB, Ernst & Young will act as Registered Advisor and the Banco de Sabadell as Liquidity Provider.
The third biotechnology company at the MAB
The EuroEspes Biomedical Research Center has today become the third Spanish company and the first Galician company of the biotechnology sector to be listed at the MAB.
EuroEspes, with its headquarters in Bergondo (Corunna, Spain) is a leading company in genomic medicine and nervous system disorders, with cutting-edge patents in nutraceutical bioproducts and pharmacogenomics.